Market Report, "China Pharmaceuticals & Healthcare Report Q1 2016", published

From: Fast Market Research, Inc.
Published: Wed Dec 16 2015

Provincial and county level healthcare markets in China will become increasingly important for multinational pharmaceutical companies. This follows government reforms to channel patient volumes to local medical facilities as well as the saturation of the major hospital markets in tier one cities. Foreign firms seeking to make this shift will have to navigate the significant variances across provinces, strong competition from local drugmakers as well as the low levels of disease awareness among the rural populace.

Headline Expenditure Projections

Pharmaceuticals: CNY608bn (USD99bn) in 2014 to CNY688bn (USD108bn) by 2015; +13.0% in local currency terms and +9.2% in USD terms.
Healthcare: CNY3,594bn (USD583bn) in 2014 to CNY4,079bn (USD640bn) in 2015; +13.5% in local currency and +9.6% in USD terms.

Risk/Reward Index

In Q116, China is amongst the most attractive countries according to our Pharmaceutical Risk/Reward Index. The country scores 63.2 out of 100 and is ranked sixth amongst 19 other Asia Pacific countries. Key to China's strong score is its high market expenditure, high sector value growth and policy continuity. The only limiting factors come from the country's business transparency and limited legal diligence.

Full Report Details at

Latest Updates

In October 2015, Tianjin CanSino Biotechnology noted its plans to start mass-producing a vaccine for the Ebola Virus.

The China Pharmaceuticals and Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's China Pharmaceuticals and Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the China pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for China, to test other views - a key input for successful budgeting and strategic business planning in the Chinese pharmaceutical and healthcare market.
* Target business opportunities and risks in the Chinese pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in China.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.


BMI Industry View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016
- Oman Pharmaceuticals & Healthcare Report Q1 2016

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »